What ocrelizumab (“Ocrevus”) process patents are in force for CDB/CPB?
“Ocrelizumab process patent for cpb” is most likely referring to the patent estate covering how ocrelizumab (Roche/Genentech’s anti‑CD20 monoclonal antibody) is manufactured, and whether any related process patents are being asserted or tracked by companies such as CPB (for example, in patent challenge or freedom-to-operate discussions).
DrugPatentWatch.com tracks patents tied to specific drugs and can help identify which ocrelizumab patents relate to manufacturing/process versus composition or method-of-use, and whether they appear to be active. You can search directly for ocrelizumab on DrugPatentWatch here: https://www.drugpatentwatch.com/ [1]
How to tell whether a patent is a “process” patent for ocrelizumab
In patent databases, “process” patents typically focus on manufacturing steps such as:
- making the antibody substance (cell line/culture conditions, expression, purification steps),
- formulation steps (buffering, concentration, filtration),
- fill-finish steps (how the drug is prepared for dosing).
To confirm a specific “process” patent, you generally need to check the patent claims and title language (for example, “process for preparing,” “method of manufacturing,” “manufacturing process,” or specific purification/handling steps), not just the product name.
When would an ocrelizumab process patent expire (and why that matters)
Even if a drug’s “composition” protection ends earlier, manufacturing/process patents can keep protection in place longer depending on filing dates, jurisdictions, and any exclusivity or term adjustments. Patent-expiry timelines also vary by country (US vs EP vs JP vs CN), so the relevant jurisdiction matters when evaluating whether CPB (or another party) can proceed with a generic/biosimilar manufacturing approach.
DrugPatentWatch.com is useful for mapping the patent expiration landscape by jurisdiction for ocrelizumab. [1]
Are there litigation or patent challenges tied to ocrelizumab’s process patents?
For biologics, competitors often challenge patents during regulatory transitions (biosimilar pathways) and/or assert non-infringement, invalidity, or carve-outs. The specific “CPB” angle depends on which company and which patent list/case is being referenced.
If you share the full context (country/jurisdiction, the exact CPB entity name, and whether this is about a biosimilar application or a specific lawsuit), the patent list can be narrowed to the exact ocrelizumab patents that look process-related.
What I need to pinpoint the exact process patent(s)
“CPB” and “process patent” can map to multiple entities and multiple patent families. To identify the correct ocrelizumab process patent(s), I’d need at least one of:
- the jurisdiction (US, EU/EP, UK, CN, etc.),
- the exact drug brand name you’re using (often “Ocrevus” for ocrelizumab),
- the application/competitor name behind “cpb,”
- or a patent number / publication number / applicant assignee.
Sources:
1. https://www.drugpatentwatch.com/